Education - Agreements, Procurement Contracts, and Memoranda of Understanding - Reporting and Publication
HB 116 updates Maryland insurance law definitions of “health benefit plan” in several subtitles of the Insurance Article to align state law with federal regulatory standards for hospital indemnity and other fixed indemnity coverage. The bill revises exclusions from the definition of a health benefit plan in the individual, small group, and other insurance contexts, replacing older Maryland-specific conditions and notice language with references to federal regulations at 45 C.F.R. § 146.145(b)(4) and 45 C.F.R. § 148.220(b)(4). In practical terms, the bill is a technical conformity measure intended to ensure that certain hospital indemnity and fixed indemnity products continue to be treated as excepted benefits under Maryland law when they meet the applicable federal criteria.
The bill affects how insurers, health carriers, and regulators classify hospital indemnity insurance, fixed indemnity insurance, and specified disease coverage. By conforming state definitions to federal rules, it may reduce inconsistency between Maryland requirements and federal standards, and it could affect whether these products are regulated as health benefit plans subject to broader insurance mandates. The bill takes effect October 1, 2025, and amends multiple sections of the Insurance Article, including provisions governing individual, small group, and other health coverage markets.
The overall sentiment appears neutral to favorable, with the bill introduced by the Chair of the Health and Government Operations Committee at the request of the Maryland Insurance Administration. That sponsorship suggests the measure is administrative and compliance-oriented rather than controversial policy legislation. No votes or committee testimony were provided in the materials, and the bill text itself reflects a narrow technical update rather than a substantive expansion or contraction of coverage.
There is little visible contention in the available record, but the main policy issue underlying the bill is the treatment of hospital indemnity and fixed indemnity products as supplemental coverage rather than comprehensive health insurance. The bill removes older Maryland-specific wording, including a required consumer notice in some provisions, and substitutes federal conformity language. Any concern would likely come from stakeholders focused on consumer disclosure, market regulation, or the boundary between supplemental insurance and major medical coverage, but no explicit opposition is shown in the provided materials.
HB 116 amends several provisions of the Maryland Insurance Article to conform the definition of “health benefit plan” to federal rules governing hospital indemnity and fixed indemnity insurance. The bill updates exclusions in the individual, small group, and other health coverage statutes so that these products are excluded when they qualify for the federal exceptions in 45 C.F.R. § 146.145(b)(4) and 45 C.F.R. § 148.220(b)(4). This changes state law by replacing older Maryland-specific criteria and notice language with federal conformity language, affecting insurers, carriers, and the Maryland Insurance Administration’s regulatory framework for supplemental health products.
The available materials suggest a generally neutral and likely supportive sentiment. The bill was requested by the Maryland Insurance Administration and introduced by the committee chair, which indicates it is a technical conformity measure aimed at aligning Maryland law with federal regulation. There is no recorded vote history or committee transcript in the provided materials, and nothing in the text suggests a partisan or policy-driven dispute.
The main point of possible contention is the treatment of hospital indemnity and fixed indemnity coverage as supplemental insurance rather than comprehensive health coverage. The bill removes Maryland-specific conditions, including a prominent consumer notice requirement in one section, and replaces them with federal regulatory references. Stakeholders concerned about consumer understanding, disclosure, or the potential for these products to be marketed as substitutes for major medical coverage could view that change cautiously, while regulators and insurers are likely to support the simplification and conformity.